Lilly Appoints VP, Early-Phase Development and Immuno-OncologyBy
Eli Lilly and Company has appointed Kimberly Blackwell, MD, as Lilly Oncology’s vice president of early-phase development and immuno-oncology, effective March 12, 2018.
Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as the co-director of the Duke women’s cancer program, associate director for strategic relations for the Duke Cancer Institute, research scholar for the Susan G. Komen Foundation, and senior strategist for the Duke Innovation and Entrepreneurship Program. She will report to Levi Garraway, MD, PhD, senior vice president, Global Development & Medical Affairs of Lilly Oncology.
Source: Eli Lilly and Company